MedPath

prospective study for treatment strategies after the decision of allogeneic HSCT in patients with MDS (KSGCT1303/ MDS-prospective)

Not Applicable
Conditions
myelodysplastic syndromes (MDS)
Registration Number
JPRN-UMIN000013144
Lead Sponsor
Kanto Study Group for Cell Therapy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with treatment-related MDS. 2.Patients who had received HSCT. 3.Patients who do not provide written informed consent.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath